Background: Despite many guidelines for the management of gestational diabetes available internationally, little work has been done to summarize and assess the content of existing guidelines. A paucity of analysis guidelines within in a unified system may be one explanatory factor. So this study aims to analyze and evaluate the contents of all available guidelines for the management of gestational diabetes. Method: Relevant clinical guidelines were collected through a search of relevant guideline websites and databases (PubMed, Web of Science, Embase, etc.). Fourteen guidelines were identified, and each guideline was assessed for quality using the Appraisal of Guidelines for Research & Evaluation (AGREE) II instrument. Two independent reviewers extracted guideline recommendations using a "recommendation matrix" through which basic guideline information and consistency between search strategy and selection of evidence, between selected evidence and interpretation, and between interpretation and resulting recommendations were analyzed. Results: Fourteen documents were analyzed, and a total of 361 original recommendations for gestational diabetes mellitus (GDM) management were assessed. In all guidelines included, the recommendations were developed in five domains, namely, diagnosis of GDM, prenatal care, intrapartum care, neonatal care and postpartum care. Different guidelines appeared to have significant discrepancy in consistency of guideline content, but overall, there was consistency between search strategy and selection of evidence, between selected evidence and interpretation, and between interpretation and resulting recommendations (scilicet 49.31, 57.20 and 58.17%, respectively). Conclusion: Although commonality in most recommendations existed, there were still some discrepancies between guidelines. Consistency of guidelines on the management of GDM in pregnancy is highly variable and needs to be improved.
Background
Gestational diabetes mellitus (GDM) is a special form of diabetes in women of child-bearing age and is a common gestational endocrine disease [1] . Due to its increasing prevalence, GDM results in significant short-and longterm impairments in the individual's health and their offspring's health [2] [3] [4] [5] [6] . Consistent evidence from high-quality randomized controlled trials over the last few decades has determined that proper management is effective in ensuring pregnancy outcomes and long-term outcomes in GDM women [7, 8] . However, management of GDM in the real world of clinical practice seems to be unsatisfactory [9] , so it is necessary to standardize the management of GDM.
Clinical practice guidelines (CPGs) are statements that include recommendations intended to assist providers and recipients of healthcare and other stakeholders to make informed decisions, and they are effective tools for disseminating medical knowledge [10] . With regard to the management of GDM, there are an abundance of available guidelines [11] [12] [13] [14] [15] [16] [17] [18] [19] . Health professional organizations like the American Diabetes Association (ADA) and the National Institute for Health and Care Excellence (NICE) update their management guidelines regularly [20, 21] . In mainland China and Hong Kong, based on international guidelines on pregnancy and diabetes mellitus, contextual guidelines for GDM management have been established through expert consensus [22, 23] . As the most authoritative form, CPGs have the potential to influence the care delivered by a large number of healthcare providers and consequently the outcomes for patients, so it is universally acknowledged that the methodological quality of guidelines is very important and should be appraised [24, 25] . Our previous research found that, in general, the quality of GDM guidelines was relatively higher than that in the previous year [26] , while the domains of Rigor of Development, Stakeholder Involvement and Editorial Independence of guidelines still needed to be improved.
However, methodological quality of guideline is not the only way to evaluate a guideline. Whether guidelines provide valid recommendations is an aspect of particular importance to practitioners. It is noted that there may be conflict between methodological quality and the validity of recommendations, and current guidelines differ substantially in their management recommendations [27] . Whether the recommendations are in accordance with evidence and whether the recommendations suit the local context are unknown. This makes it hard for the busy practitioners, confronted with conflicting guideline recommendations, to determine which guideline to follow [27] . Many researchers are aware of the fact that it is imperative to find a unified system for evaluating the validity of recommendations. However, little work has been done in this area. In order to better ascertain the best treatment for GDM women and whether recommendations in current guidelines are valid or not, extracting and appraising the content of current guidelines are crucial. Therefore, the aim of this study was to extract and evaluate the recommendations included in guidelines for GDM management using a recommendation matrix (details in another article under review).
Methods
A search was conducted in CPGs for GDM management. The search strategy used the keywords "pregnancy", "gravida*", "conception", "maternity", "diabetes", "hyperglycemia", "insulin resistance", "glucose intolerance", "guideline", "criteria", "recommendation" and "standard". Information sources were identified from the National Institute for Health Based on the quality evaluations, the reviewers summarized recommendations in guidelines and assessed the content of guidelines by establishing a "recommendation matrix" (Table 1 as an example). For each included document, we extracted the following information: title of guideline, author, development institute (e.g. government, special organization, etc.), year of publication, guideline type, methodological quality (appraised with AGREE II) and relevant recommendations. For all recommendations extracted, we assessed whether or not they explicitly recommended with the consistency across search strategies, selection of evidence, evidence interpretation and resulting recommendations. Each of the recommendations was rated on a seven-point scale (1-strongly inconsistent to 7-strongly consistent). A quality score was calculated in the same way used in AGREE II [28] , that is, for each recommendation, the score was calculated by summing up all the scores of the individual items and by scaling the total as a percentage of the maximum possible score [28] . If the guideline provided more complete information, we also extracted supporting evidence and the evidence level if the evidence has been cited, and the likelihood of applying the recommendation in China. For all guidelines, the recommendations were divided into five domains, namely, diagnosis of GDM, prenatal care, intrapartum care, neonatal care and postpartum care.
Initially, two researchers (Yingfeng Zhou and Mengxing Zhang) independently analyzed one guideline with the recommendation matrix in order to identify the validation and feasibility of the tool before determine the final result. Then the final form was used to extract recommendations content from the other guidelines. Frequent communication occurred between two researchers throughout the process so as to maximize inter-rater reliability. Any disagreements were settled through consultation with the study groups.
Descriptive statistics were conducted in order to characterize the recommendation content. For quantitative data, the statistical analysis was performed using Microsoft Office 2013 and SPSS Version 25.0. The total number, percentages, and mean, and standard deviation were calculated to describe the consistency of recommendations. In addition, a radar chart was also used to identify features of recommendation consistency in different aspects.
This article is part of a guideline adaptation project. The Guideline Adaptation Project has been registered in the International Guideline Register Center (http://www.guidelines-registry.cn), Registration number: IPGRP-2016CN015.
Results

Characteristics of included guidelines
Combining all searches yielded 108 relevant documents, of which 14 guidelines from international organizations Table 2 .
According to systematically evaluation with AGREE II instrument, the methodological quality of guidelines included varied. But generally, they scored well. Scores for six AGREE II domains (Mean ± SD) were:88% ± 0.15 (Scope and Purpose), 73% ± 0.30 (Stakeholder Involvement), 60% ± 0.29 (Rigor of Development), 89% ± 0.19 (Clarity of Presentation), 70% ± 0.34 (Applicability), 70% ± 0.41 (Editorial Independence).
Comparison and summary of recommendations
Using the recommendation matrix, all relevant guideline information and recommendations included were extracted, and all health questions of each guideline were placed in the recommendation matrixes (Additional files 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14) . For example, we extracted the NICE guideline, which is displayed in Table 1 . The NICE guideline was developed based on evidence, and the development process was The effectiveness categorization of each domain based ons the recommendations was presented in Table 3 . The similarities and differences between the different guidelines on each domain were discussed below.
Diagnosis of GDM
The first domain was diagnosis of GDM, which covered three health questions: risk factors of GDM, GDM To address the issue of GDM, FIGO recommends the following: ①Public health focus; ②Universal testing; ③Criteria for diagnosis; ④Diagnosis of screening and diagnostic criteria. Risk factors for GDM were identified in five guidelines [12, [21] [22] [23] 29] , mainly including personal and family history, relevant medical history, past pregnancy and current history. It was noted that threshold of some risk factors were discrepant in different guidelines. As an example, advanced maternal age, obesity BMI and macrosomia weighing in Hong Kong College of Obstetricians and Gynaecologists (HKCOG) guideline [22] had a much smaller value then in western countries. NICE guideline recommended that pregnant women with risk factors should be screened, while other guidelines recommended that universal screening was preferred. As to diagnostic criteria, the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) (2010) criteria was adopted by most guidelines. In this study, eight guidelines [11, 13, 16-18, 22, 23, 29] included used IADPSG (2010) criteria, recommending that GDM should be diagnosed at any time in pregnancy if one or more of the following criteria were met following a 75 g oral glucose tolerance test (OGTT): 1) fasting PG 5.1-6.9 mmol/L; 2) 1-h PG ≥ 10.0 mmol/L; 3) 2-h PG 8.5-11.0 mmol/L, while six other guidelines recommended alternatives.
Prenatal care
Prenatal care was a very crucial domain of GDM management. All guidelines agreed that it was necessary to encourage GDM women to take prenatal care. All guidelines, excepting the A.N.D. guideline [11] that only mentioned nutrition therapy, made recommendations in similar aspects of prenatal interventions more or less, which might refer to health education, medical nutrition therapy, physical activity, pharmacological therapy, blood glucose monitoring, target blood glucose values, ketone monitoring, HbA1c monitoring, continuous glucose monitoring and fetal assessment. The main principles included: ①offer all women ongoing treatment by multidisciplinary health professionals once they were diagnosed; ②life-style intervention was a primary and essential component of management, especially nutrition therapy; ③medical therapy should be started if needed to achieve glycemic targets; and ④ self-monitoring of blood glucose regularly should be emphasized. However, recommendations of a similar theme were not always unanimous in different guidelines. For example, six guidelines [12, 14, 19, 20, 23, 29] recommended that insulin was the preferred medication for treating hyperglycemia in GDM. On the contrary, other six guidelines [13, 16-18, 21, 22] did not regard insulin as the first option when drug treatment was required, since it was proved that oral antidiabetic agents was safe and might even significantly reduce several adverse maternal and neonatal outcomes (Table 4 ). In addition, women's preferences and the ability to adhere to medication and self-monitoring were also considered in different guidelines.
Intrapartum care
The intrapartum care domain contained timing and mode of birth and glycemic control. Each guideline differed slightly on recommendations for timing and mode of birth, however, commonality in the way in which timing and mode of birth was decided was described, in other words, depending on whether there were maternal or fetal complications. Recommendations for glycemic control during labor and birth were similar for most guidelines, namely, monitoring capillary plasma glucose during labor and birth, and ensuring that it was maintained in normal glucose values (five guidelines [12, 13, 17, 18, 21] recommended to maintain blood glucose levels between 4 and 7 mmol/L).
Neonatal care
The fourth domain was neonatal care, that is, neonatal hypoglycemia and neonatal initial assessment. Only five guidelines [12, 15, 17, 21, 23 ] mentioned recommendations for neonatal hypoglycemia, advising to avoid neonatal hypoglycemia through measuring the infant's plasma glucose frequently and early feeding. In addition, for newborns who had clinical signs associated with neonatal complications, NICE guidelines also made additional recommendations for neonatal initial assessment and criteria for admission to intensive or special care.
Postpartum care
Postpartum care was a domain involving medicines and breastfeeding after delivery, information and follow-up after birth and postnatal testing. Most guidelines recommended that GDM women should discontinue blood glucose-lowering therapy immediately after birth, but HKCOG guidelines [22] emphasized that those women could also resume or continue to take metformin and glibenclamide after birth as required. Early and exclusively breastfeeding was highly encouraged, for its benefits for both mother and infant. Regarding postnatal education, it was unanimously agreed in all guidelines that women diagnosed with GDM should be informed of the increased risk of GDM in a subsequent pregnancy and the increased risk for developing type 2 diabetes. Hence, it was important to provide them with advice on how to maintain a healthy lifestyle and information on postnatal testing. Recommendations for postnatal testing were slightly different.
The method of postnatal testing can be OGTT or HbA1c (with or without fasting glucose). And testing time ranged from the initial month to 6 months, mainly between six to 12 weeks after birth. Then assessment of glycemia using fasting glucose or HbA1c should be carried out at regular intervals thereafter. ① Offer metformin to women with gestational diabetes if blood glucose targets are not met using changes in diet and exercise within 1-2 weeks; ② Offer insulin instead of metformin to women with gestational diabetes if metformin is contraindicated or unacceptable to the woman; ③ Consider glibenclamide for women with gestational diabetes: in whom blood glucose targets are not achieved with metformin but who decline insulin therapy or who cannot tolerate metformin.
NZGG, 2014
Where women who have gestational diabetes and poor glycaemic control (above treatment targets) in spite of dietary and lifestyle interventions, offer oral hypoglycaemics (metformin or glibenclamide) and/or insulin therapy. In deciding whether to use oral therapy or insulin, take account of the clinical assessment and advice, and the woman's preferences and her ability to adhere to medication and self-monitoring.
SIGN, 2013
Metformin or glibenclamide may be considered as initial pharmacological, glucose-lowering treatment in women with gesta tional diabetes.
ADA, 2018
Insulin is the preferred medication or treating hyperglycemia in gestational diabetes mellitus as it does not cross the placenta to a measurable extent. Metformin and glyburide may be used, but both cross the placenta to the fetus, with metformin likely crossing to a greater extent than glyburide. All oral agents lack long-term safety data.
FIGO, 2015
① Insulin, glyburide, and metformin are safe and effective therapies for GDM during the second and third trimesters, and may be initiated as first-line treatment after failing to achieve glucose control with lifestyle modification. Among OADs, metformin may be a better choice than glyburide; ② High resource: Insulin should be considered as the first-line treatment in women with GDM who are at high risk of failing on OAD therapy, including some of the following factors: ① We suggest that glyburide (glibenclamide) is a suitable alternative to insulin therapy for glycemic control in women with gestational diabetes who fail to achieve sufficient glycemic control after a 1-week trial of medical nutrition therapy and exercise except for those women with a diagnosis of gestational diabetes before 25 weeks gestation and for those women with fasting plasma glucose levels > 110 mg/dl (6.1 mmol/l), in which case insulin therapy is preferred; ② We suggest that metformin therapy be used for glycemic control only for those women with gestational diabetes who do not have satisfactory glycemic control despite medical nutrition therapy and who refuse or cannot use insulin or glyburide and are not in the first trimester.
CDA, 2013
① If women with GDM do not achieve glycemic targets within 2 weeks from nutritional therapy alone, insulin therapy should be initiated; ② For women who are nonadherent to or who refuse insulin, glyburide or metformin may be used as alternative agents for glycemic control. Use of oral agents in pregnancy is off-label and should be discussed with the patient.
API, 2014
The use of OADs is currently not recommended for glycaemic management during pregnancy.
IDF, 2009
Insulin has been, and is likely to remain, the treatment of choice but there is now adequate evidence to consider the use of metformin and glibenclamide (glyburide) as treatment options for women who have been informed of the possible risks. Combination therapy has not been specifically studied.
Queensland, 2015 ① Metformin when compared to Insulin is effective at lowering blood glucose and is safe for pregnant women and their fetuses; ②I nsulin is safe to use in pregnancy.
HKCOG, 2016 ① Offer metformin if blood glucose targets are not met after diet and exercise therapy within 1-2 weeks; ② Offer addition of insulin to diet therapy, exercise and metformin if blood glucose targets are not met. ③ Consider glibenclamide for women in whom blood glucose targets are not achieved with metformin but who decline insulin therapy or who cannot tolerate metformin.
CMA, 2014
Insulin should be considered as the first-line treatment in women with GDM, and OADs is currently not recommended for gly caemic management during pregnancy.
DDG, 2018
① The indication for insulin should first be considered within 1-2 weeks after the start of basic therapy (diet, exercise); ② For pregnant women with GDM and suspected severe insulin resistance and when individually indicated, use of metformin can be considered following explanation of the off-label use.
Assessment of consistency
A total of 361 original recommendations for GDM management which were from 14 guidelines were included. Although some recommendations did not fall into any of the identified themes, we undertook consistency appraisal of these as well. As presented in Table 5 , different guidelines appeared to have significant discrepancies in consistency of guideline content. Even in the same guideline, consistency differed in three aspects: ①consistency between search strategy and selection of evidence, ②consistency between selected evidence and interpretation, and ③consistency between interpretations and resulting recommendations. Among all guidelines included, NICE guidelines showed the best average score of consistency in each aspect. However, HKCOG guidelines and CMA guidelines received extremely low scores in each aspect. Apparently, in this study, evidence-based guidelines rated relatively higher in content consistency than expert consensus-based guidelines. Consistency appraisal of each guideline is presented in Fig. 2 . For consistency in each aspect, most guidelines showed the same tendency, that is, a guideline which received high average scores could also receive high scores in the other two aspects, and, conversely, low average scores in all aspects. When it came to all recommendations, search strategy and selection of evidence were slightly inconsistent. The radar chart showing comparable consistency between search strategy and selection of evidence, between selected evidence and interpretation, and between interpretation and resulting recommendations (scilicet 49.31, 57.20 and 58.17%, respectively) is presented in Fig. 3 .
Discussion
Gestational diabetes mellitus is a challenging complication of pregnancy that many women and doctors struggle with. In this review, we examined the existing guidelines on the management for GDM in 11 countries or regions. Given that appropriate methodologies and rigorous strategies in the guideline development process are crucial for guideline implementation [25] , the development methods of the guidelines were measured using the AGREE II instrument. In general, the quality of GDM guidelines, especially evidence-based guidelines, was high. This could be explained by the fact that much progress has been made in the development of methodological and reporting criteria of evidence-based guidelines within the past decade [30] . Nonetheless, as the results in previous study revealed, the domains of Rigor of Development, Stakeholder Involvement and, Editorial Independence still need to be improved [26] . It is noted that practice guidelines with the best methodological quality were not necessarily the most valid in their recommendations [27] . Thus it is important to emphasize that clinical practitioners should critically evaluate the methodological quality as well as the content of the recommendations before adopting the recommendations, which leads to another issue, that is, consistency appraisal. Despite many researchers being aware of the crucial role of the appraisal of consistency between evidence and resulting recommendations, there are no existing criteria for assessing content consistency of guidelines. In guideline adaptation of some topics, qualitative analysis was used in content extraction, which formulated a general description of the research topic through generating categories without any consistency appraisal [31, 32] . In this review, we developed a "recommendation matrix" on the basis of the CAN-Implement© method [33] , and used the tool to extract and assess guideline content. As a recommendation matrix was used, not only relevant and potentially relevant recommendations on all pre-specified healthcare aspects for GDM care were identified, but also consistency between search strategy and selection of evidence, between selected evidence and interpretation, and between interpretation and resulting recommendations was assessed. The results showed that current guidelines on GDM care are of varied consistency, and guidelines developed in internationally recognized guideline development methodology show better consistency. Also guidelines that have low consistency in one aspect may also have low consistency in other two aspects. This is probably because reporting quality of guidelines is the cornerstone of consistency assessment. Those guidelines with evidence tables or technical reports not published may also show low consistency. Thus, guideline development committees are strongly encouraged to make use of guideline development manuals when drafting guidelines. Regarding guideline content, five aspects were analyzed: diagnosis of GDM, prenatal care, intrapartum care, neonatal care, and postpartum care. Most recommendations in guidelines focused on prenatal care, especially all kinds of therapies that might reduce the risk of adverse pregnancy outcomes related to uncontrolled blood sugar preconception. This review generated similar results with those from a previous study that international guidelines were consistent in most of their recommendations [34] . Nonetheless, although commonality in most areas existed, there were still some discrepancies among guidelines. For example, recommendations regarding oral hypoglycemic agents in the guidelines diverged. Some guidelines recommended that oral hypoglycemic agents be considered as an initial pharmacological intervention, while some guidelines only considered insulin as an exclusive hypoglycemic medicine. Guidelines were supported with evidence, so inconsistency may be caused by insufficient evidence on pharmacological interventions in the period in which the guidelines were developed [26] . However, it should be reminded that even though all evidence available was identified, consensus usually did not warrant similar recommendations in different contexts. This was because when a recommendation was developed, not only available evidence, but benefits and harms, patients' values and preferences, as well as resource implications, should be appropriate considered [10] .
Since recommendations were well summarized, guideline adaptation was required to maintain the validity of recommendations in different health care systems. Guideline adaptation involves using knowledge synthesis of existing guidelines to produce recommendations, rather than relying only on a review of primary literature, for the purpose of reducing duplication of effort [35] . In mainland China and Hong Kong, there were only expert consensus for GDM care [22, 23] , without a national GDM management evidence-based guideline adapted to the Chinese context previously. In this instance, it is recommended to adapt the clinical practice guideline related to GDM management for the local context, providing support for professionals to make better decisions in clinical practice. How to select, tailor and implement recommendations and supporting evidence extracted is the next challenging step.
Limitation
Due to the language barriers, we only included guidelines in English and Chinese. As a result, we only got existing guidelines on the management for GDM in 11 countries or regions in this review. And yet, we have no idea whether other countries use the recommendations provided by a certain guideline or use recommendations developed in their own language.
Another key limitation of this study is the subjectivity in appraising the consistency between evidence and recommendations. Although we attempted to minimize these discrepancies by stating the assessment criteria and through rigorous discussion, the results of the consistency appraisal still varied because of different understandings between researchers. Additionally, reporting quality of some guidelines is not clear cut, which was another barrier in the process of content analysis. Apart from this, this is the first time that we used a "recommendation matrix" in content analysis, and the tool we developed may still need to be modified.
Conclusion
This paper describes the process used to extract and access the content of guidelines for GDM management. In conclusion, the recommendations were developed in five aspects: diagnosis of GDM, prenatal care, intrapartum care, neonatal care and postpartum care. The consistency of guidelines on the management of GDM in pregnancy is highly variable and this inconsistency needs to be addressed. Also, this review has proven that a "recommendation matrix" can be a tool to extract and assess consistency of guidelines. Additionally, our findings indicated that it is necessary to adapt and disseminate easily understandable evidence-based guidelines based on knowledge synthesis of existing guidelines in this paper.
